Menu
Recruiting NCT04366804

International Validation of Two Non-motor Scales in PD (NFS and SPARK)

Observational Parkinson's Disease Non-motor Symptoms

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Parkinson's Disease, Non-motor Symptoms. Basic parameters: 30 years — 75 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France, Germany, Greece, Romania, Spain +2
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

International Validation of Two Non-motor Scales in Parkinson's Disease: the Neuropsychiatric Fluctuations Scale (NFS) and the Shame in Parkinson's Disease (SPARK) Scale

Overview

The goal of this project is to develop the international validation of two new rating scales, the Neuropsychiatric Fluctuations Scale (NFS) and the Shame in PARKinson's disease (SPARK) Scale, in order to improve the understanding of the extent and severity of non-motor symptoms in Parkinson's disease (PD).

Detailed description

This project is a prospective international multicentre study to validate two new rating scales in different languages: the Neuropsychiatric Fluctuations Scale (NFS) and the Shame in PARKinson's disease (SPARK) Scale.

The project population consists a minimum of 300 PD patients with and without fluctuations in the participant countries: Spain, Germany, France, Switzerland, Romania and Greece.

The NFS is specifically designed to detect neuropsychiatric fluctuations between off- and on-medication condition in PD. It is composed of 20 items, 10 items measuring the on-neuropsychological symptoms and 10 items for the off-neuropsychological manifestations. The validation of this scale, based on the most frequently experienced symptoms by the patients, would allow a crucial breakthrough in the improvement of management of PD patients.

Shame and embarrassment are poorly recognized by physicians in PD. PD-related shame and embarrassment may emerge from motor and non-motor symptoms, from self-perception of inadequacy due to loss of autonomy and need for help, or from perceived deterioration of body image. The current available scales are not specific for PD. Based on reports of persons affected with PD and a literature review about shame and stigmatization in PD a 25-items self-questionnaire for shame and embarrassment in PD was created. The scale includes 6 different subscales (1. Shame arising from PD symptoms; 2. Shame arising from the increasing physical dependence and need for help induced by PD; 3. Shame arising from the patient's assumption of breaking certain social rules; 4. Shame arising from the deteriorated body image; 5. Consequence of related shame and embarrassment on patients' health-related quality of life; 6. Stigmatization). The validation of this scale will give a tool for physicians and researchers to better understand the impact of PD on patient's quality of life.

Primary outcome measures

  • NFS score [Time frame: 2 weeks (2 assessments in a time span of 2 weeks)]
  • SPARK score [Time frame: 2 weeks (2 assessments in a time span of 2 weeks)]

Eligibility criteria

Inclusion criteria

  • Written informed consent;
  • PD, according to the MDS criteria;
  • Age of participants > 30 and < 75 years;
  • Being fluent in the language in which the scales are applied.

Exclusion criteria

1\. Presence of PD dementia (defined as MoCA score < 24).

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

Spain · 2 centers
  • Hospital Universitario Burgos — Burgos
  • Ruber International Hospital — Madrid
France · 1 center
  • Centre hospitalier régional universitaire de Besançon — Besançon
Germany · 1 center
  • Universitätsklinikum Carl Gustav Carus — Dresden
Greece · 1 center
  • Aristotle University of Thessaloniki — Thessaloniki
Romania · 1 center
  • Transilvania University — Brasov
Switzerland · 1 center
  • Insel Gruppe AG University Hospital Bern — Bern
United Kingdom · 1 center
  • King's College London — London

Identifiers

NCT: NCT04366804 · 2020-00303

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗